Douglas M. Crumb Appointed President of Xhale, Inc.
GAINESVILLE, FL June 2, 2015
Xhale, Inc., a medical technology company developing and commercializing unique monitoring solutions for the pharmaceutical and healthcare industries, announced the appointment of Douglas M. Crumb to the role of President and Chief Operating Officer of the company. In this position, Mr. Crumb is responsible for completing the commercial launch of Xhale’s Assurance® and SMART® product lines, and leading the company’s highly-skilled team as they deliver medication adherence monitoring to the pharmaceutical industry and advanced patient monitoring to the hospital and healthcare industry.
Mr. Crumb joined Xhale in 2012 as Vice President of Operations, before advancing to the role of Chief Operating Officer in 2014. He has extensive experience with medical device companies in both the private equity and publicly traded sectors, including having managed multiple manufacturing facilities while VP of Operations for ConMed Corporation, and overseeing the construction and startup of a large ConMed medical manufacturing operation in Mexico. Prior to that role, Mr. Crumb was VP of Operations for Smiths Medical – DHD Healthcare, and after ConMed Mr. Crumb served as VP of Operations, Engineering/R&D, Quality and Regulatory for IZI Medical Products. Mr. Crumb’s areas of special expertise include lean manufacturing, project management, product development and driving profitability. He holds a Masters in Advanced Engineering from the State University of New York.
“I am extraordinarily pleased to announce the appointment of Douglas Crumb to the role of President of Xhale,” said Richard R. Allen, CEO of the company. “Douglas has demonstrated gifted leadership over the past three years, and has been vital to our success as we bring these important technologies to the market. His expertise and leadership will advance the mission of Xhale, which is to make the drug development process more effective, less risky and less costly, and to provide more effective patient monitoring”.
Xhale, Inc. is a medical technology company commercializing two broad technology platforms for the healthcare industry. Through its subsidiary Xhale Smart, Inc. the company is commercializing it’s breath-based medication adherence monitoring system called SMART®. SMART® reports – in real-time, via wireless cellular to the web – whether a participant in a pharmaceutical clinical trial has swallowed the medication and if the medication reached their stomach, addressing the problem of the large number of clinical trial participants who aren’t taking the study drug or following the dosing protocol. Through its Xhale Assurance, Inc. subsidiary, Xhale is commercializing the Assurance® pulse oximetry sensor, a simple, highly-effective single-point-of-contact sensor that can reliably monitor critical parameters under challenging conditions for patients.
Xhale, Inc. was founded in 2005 on technology licensed from the University of Florida. For more information, please visit www.xhale.com or contact the company at email@example.com.